Veracyte, Inc. - Common Stock (NQ:VCYT)

45.81 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

September 28, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

September 24, 2025

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

September 09, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 29, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

August 26, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

August 27, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential ↗

August 13, 2025

Veracyte (VCYT) emerges as a potential value stock with strong valuation, profitability, and growth metrics in the biotech sector, backed by solid financial health and cash flow potential.

Via Chartmill

Veracyte (VCYT) Q2 Revenue Jumps 14% ↗

August 07, 2025

Via The Motley Fool

Veracyte Announces Second Quarter 2025 Financial Results

August 06, 2025

From Veracyte, Inc.

Via Business Wire

Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics ↗

July 26, 2025

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.

Via Benzinga

VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals ↗

July 21, 2025

VERACYTE INC (NASDAQ:VCYT) is an undervalued biotech stock with strong financial health, solid profitability, and impressive growth prospects, making it a candidate for value investors.

Via Chartmill

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

July 17, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

July 08, 2025

From Veracyte, Inc.

Via Business Wire

Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet ↗

June 21, 2025

Via Benzinga

Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems ↗

June 07, 2025

Ark Invest made notable trades on Friday, including purchasing shares of Veracyte Inc. and selling shares of 3D Systems Corp.

Via Benzinga

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

May 28, 2025

From Veracyte, Inc.

Via Business Wire

VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology ↗

May 28, 2025

VERACYTE INC (NASDAQ:VCYT) is a biotechnology stock with strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth...

Via Chartmill

Veracyte to Participate in Upcoming Investor Conferences

May 20, 2025

From Veracyte, Inc.

Via Business Wire

Breaking Down Veracyte: 7 Analysts Share Their Views ↗

May 08, 2025

Via Benzinga

Veracyte Announces First Quarter 2025 Financial Results

May 07, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch ↗

May 02, 2025

Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch

Via Chartmill

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms ↗

April 26, 2025

ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details.

Via Benzinga

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

April 25, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

April 22, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release

April 21, 2025

From Veracyte, Inc.

Via Business Wire

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. ↗

April 17, 2025

A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Via Investor's Business Daily

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

April 16, 2025

From Veracyte, Inc.

Via Business Wire

Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability. ↗

April 12, 2025

Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.